Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment (Q40725226)

23 September 2017

1 reference

title

Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment (English)

1 reference

23 September 2017

1 reference

Wheeler DC

1

1 reference

23 September 2017

Bernard DB

series ordinal

2

1 reference

23 September 2017

publication date

1 March 1994

1 reference

American Journal of Kidney Diseases

23 September 2017

published in

1 reference

23 September 2017

volume

23

1 reference

23 September 2017

issue

3

1 reference

23 September 2017

page(s)

331-346

1 reference

Frequency of risk factors for ischaemic heart-disease in a healthy British population. With particular reference to serum-lipoprotein levels

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

The nephrotic syndrome, lipids, and risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Treatment of hyperlipidemia in nephrotic syndrome: time for a change?

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

The receptor model for transport of cholesterol in plasma

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipoprotein (a). Heterogeneity and biological relevance

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Serum lipid and lipoprotein alterations in nephrosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipoprotein distribution and composition in the human nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipoprotein profiles at different stages of the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Low-density lipoprotein metabolism in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Hyperlipoproteinemia in nephrosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Serum and urinary high density lipoproteins in glomerular disease with proteinuria

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Pathogenesis and management of lipoprotein disorders

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipoprotein(a) in patients with proteinuria

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

A fresh look at the atherogenic remnant hypothesis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Hyperlipidaemia of diabetes

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Hepatic Secretion of Lipoproteins in the Rat and the Effect of Experimental Nephrosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Studies on the synthesis and secretion of serum lipoproteins by rat liver slices

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis. I: Studies in rat in vivo

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Increased hepatitic cholesterol production due to liver hypertrophy in rat experimental nephrosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside. Plasma and urinary lipoproteins

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Effects of dextran, polyvinylpyrrolidone and gamma globulin on the hyperlipidemia of experimental nephrosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat.

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Impaired renal mevalonate metabolism in nephrotic syndrome: a stimulus for increased hepatic cholesterogenesis independent of GFR and hypoalbuminemia

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Studies on the metabolism of plasma proteins in the nephrotic syndrome. II. The lipoproteins

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal?

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Urinary excretion of apolipoproteins bound to HDL-like particles in rat nephrotic syndrome and their relation to plasma HDL

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

The effect of α1-acid glycoprotein (orosomucoid) on triglyceride metabolism in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Characterization of glycosaminoglycans in urine from patients with nephrotic syndrome and control subjects, and their effects on lipoprotein lipase

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

High-density lipoprotein apolipoprotein AI and AII turnover in moderate and severe proteinuria

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

High density lipoproteinuria in nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis.

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Experimental nephrotic syndrome: removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

The mechanism of hyperlipidaemia in nephrotic syndrome--role of low albumin and the LCAT reaction

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Plasma lipids and acyltransferase activities in experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Role of oxidized low density lipoprotein in atherogenesis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Extrarenal complications of the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Ischaemic heart-disease as a complication of nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Does the nephrotic syndrome increase the risk of cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Cardiovascular Disease and the Nephrotic Syndrome: the other Side of the Coin

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

The Nephrotic Syndrome and Ischaemic Heart Disease

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

The increased risk of coronary heart disease associated with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Glomerular disease in hypercholesterolemia guinea pigs: A pathogenetic study

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipids and the kidney

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Effects of dietary fatty acids in an animal model of focal glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Oxidized low-density lipoprotein in experimental focal glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Mesangial function and glomerular sclerosis in rats after unilateral nephrectomy

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Renal handling of plasma high density lipoprotein

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

LDL stimulates mesangial fibronectin production and chemoattractant expression

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Focal and segmental glomerulosclerosis: analogies to atherosclerosis

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Primary hyperlipidaemia is not associated with increased urinary albumin excretion

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Relation between serum cholesterol and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Partial remission of nephrotic syndrome in patient on long-term simvastatin

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Management of hyperlipidemia of kidney disease

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Cardiovascular Effects of n-3 Fatty Acids

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Polyunsaturated fatty acids, hyperlipidemia, and thrombosis.

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Clinical applications of fish oils

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

n-3 fatty acids reduce proteinuria in patients with chronic glomerular disease

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Dietary fish oil interferes with renal arachidonic acid metabolism in rats: correlations with renal physiology

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Treatment of nephrotic hyperlipoproteinemia with gemfibrozil

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atheroscleros

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Effect of probucol on hyperlipidemia in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

Long-Term Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Patients With Nephrotic Proteinuria

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(12)80994-2

7 January 2021

10.1016/S0272-6386(12)80994-2

Identifiers

DOI

1 reference

23 September 2017

1 reference